首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1471991

前列腺癌治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按治療類型、最終用戶和地理位置

Prostate Cancer Treatment Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type, End Users, and Geography

出版日期: 2024年03月22日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

攝護腺癌治療市場預計將從2022年的190.7億美元成長到2030年的341.1億美元；預計2022年至2030年複合年成長率為7.5%。

前列腺癌是男性最常見的健康問題之一，尤其是老年男性（50歲以上）。在明顯症狀的情況下發展，因此，這種癌症的早期發現並不容易。對尿道施加壓力，或在某些情況下，轉移引起的骨痛可能是晚期前列腺癌的首發症狀，但是，任何50 歲或以上出現下泌尿道症狀、勃起功能障礙或血尿的個體都應考慮。攝護腺癌的可能性是全球男性癌症死亡的第五大原因，也是第二常見的癌症。

不斷增加的策略性措施推動前列腺癌治療市場的成長。

在前列腺癌治療市場營運的小型和大型公司採取各種策略，例如地理擴張、新產品發布和技術進步來增加收入。以下提到了前列腺癌治療市場的一些最新發展。

2023年11月，FDA批准了安斯泰來製藥美國公司生產的恩雜魯胺，用於治療具有高轉移風險的生化復發的非轉移性去勢敏感型前列腺癌（nmCSPC）（高風險BCR））。

2023年11月，安斯泰來製藥公司收購了Propella Therapeutics Inc.和PRL-02（阿比特龍癸酸酯），PRL-02是Propella開發的用於治療前列腺癌的下一代雄激素生物合成抑制劑。

2023年4月，FDA授予Lantheus Holdings Inc.和POINT Biopharma Global Inc. 177Lu-PNT2002治療轉移性去勢抵抗性前列腺癌（mCRPC）的快速通道資格。 PNT2002是一種創新的PSMA靶向177Lu放射性藥物療法，結合了PSMA靶向配體、PSMA-I&T和BETA發射放射性同位素無載體177Lu，用於治療mCRPC。

2023年6月，阿斯特捷利康和默沙東的Lynparza（olaparib）合併潑尼鬆或潑尼松龍和阿比特龍在美國被批准用於治療疑似有害BRCA突變（BRCAm）轉移性去勢抵抗性前列腺癌（mCRPC）的成年患者。

2023 年2 月，Fusion Pharmaceuticals Inc. 宣布從RadioMedix, Inc.（「RadioMedix」）收購研究性新藥申請（「IND」），用於正在進行的評估225Ac-PSMA 的2 期臨床試驗（「TATCIST」試驗） I&T，一種針對前列腺癌上表達的前列腺特異性膜抗原（“PSMA”）的小分子。交易結束後，TATCIST 試驗中正在評估的α發射放射性藥物命名為 FPI-2265。

2022年3月，美國FDA核准諾華公司的Pluvicto（镥Lu 177 vipivotide tetraxetan）用於治療晚期前列腺癌（稱為前列腺特異性膜抗原陽性轉移性去勢抗性前列腺癌（PSMA陽性mCRPC））的成年患者。

市場參與者積極參與擴張、合作和併購，促進了前列腺癌治療市場的成長。

前列腺癌治療市場報告的範圍涵蓋北美（美國、加拿大和墨西哥）、歐洲（西班牙、英國、德國、法國、義大利和歐洲其他地區）、亞太地區（韓國、中國、印度、日本、澳洲和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地區）。北美是全球前列腺癌治療市場成長的最大貢獻者。預計 2022 年至 2030 年，亞太地區的前列腺癌治療市場複合年成長率最高。美國前列腺癌治療市場的成長主要是由前列腺癌發病率上升、產品發布和政府舉措推動的。公司推出的各種治療前列腺癌的產品也促進了市場的成長。例如，2023年6月，阿斯特捷利康和默沙東的Lynparza（olaparib）合併潑尼鬆或潑尼松龍和阿比特龍在美國被批准用於治療疑似有害BRCA突變（BRCAm）轉移性去勢抵抗性前列腺癌（mCRPC）的成年患者）。此外，2023年11月，FDA批准了Astellas Pharma US, Inc.生產的恩雜魯胺（enzalutamide），用於治療具有高轉移風險（高風險）生化復發的非轉移性去勢敏感型前列腺癌（ nmCSPC）。

世界衛生組織 (WHO)、疾病管制與預防中心 (CDC) 以及食品藥物管理局 (FDA) 是在準備前列腺癌治療市場報告時提到的幾個關鍵的主要和次要來源。

概述
治療類型市場預測與分析
荷爾蒙療法
- 概述
- 荷爾蒙治療市場預測與分析
化療
- 概述
- 化療市場預測與分析
免疫治療
- 概述
- 免疫療法市場預測與分析
標靶治療
- 概述
- 標靶治療市場預測與分析
手術
- 概述
- 手術市場預測與分析
放射治療
- 概述
- 放射治療市場預測與分析

第 8 章：前列腺癌治療市場 - 2031 年收入和預測 - 分銷管道

概述
分銷通路市場預測與分析
醫院
- 概述
- 醫院市場預測與分析
診所
- 概述
- 診所市場預測與分析
其他
- 概述
- 其他市場預測與分析

第 9 章：前列腺癌治療市場收入和 2031 年預測 - 地理分析

北美洲
- 北美洲
- 歐洲
- 亞太
- 中東和非洲
- 南美洲和中美洲

第 11 章：產業格局

併購
協議、合作和合資企業
新產品發布
擴張和其他策略發展

第 12 章：前列腺癌治療市場，主要公司概況

JOHNSON AND JOHNSON
ASTELLA PHARMA INC.
SANOFI
DENDREON PHARMACEUTICALS LLC
CARDINAL HEALTH
ASTRAZENECA
BAYER AG
TOLMAR INC
ENDO PHARMACEUTICALS INC
ABBVIE, INC.

第 13 章：附錄

簡介目錄

Product Code: TIPRE00021050

The prostate cancer treatment market is expected to grow from US$ 19.07 billion in 2022 to US$ 34.11 billion by 2030; it is anticipated to record a CAGR of 7.5% from 2022 to 2030.

Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years. Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that is it often develops without noticeable symptoms and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra or in some cases bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Prostate cancer is the 5th leading cause of cancer death among men worldwide and the 2nd most commonly diagnosed cancer.

Increasing Strategic Initiatives Propels Prostate Cancer Treatment Market Growth.

Small and big companies operating in the prostate cancer therapeutics market adopt various strategies such as geographic expansion, new product launches, and technological advancements to boost their revenues. A few recent developments in the prostate cancer treatment market are mentioned below.

In November 2023, the FDA approved enzalutamide, a product manufactured by Astellas Pharma US, Inc. which is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).

In November 2023, Astellas Pharma Inc. acquired Propella Therapeutics Inc. and PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor developed by Propella to treat prostate cancer.

In April 2023, the FDA granted Lantheus Holdings Inc. and POINT Biopharma Global Inc. fast track designation for 177Lu-PNT2002 to treat metastatic castration-resistant prostate cancer (mCRPC). PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines PSMA-targeted ligand, PSMA-I&T, and beta-emitting radioisotope no-carrier-added 177Lu for treating mCRPC.

In June 2023, AstraZeneca and MSD's Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US to treat the adult patients who suffer from suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

In February 2023, Fusion Pharmaceuticals Inc. announced the acquisition from RadioMedix, Inc. ("RadioMedix") of the investigational new drug application ("IND") for an ongoing Phase 2 clinical trial (the "TATCIST" trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial named as FPI-2265.

In March 2022, the US FDA approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treating adult patients with a type of advanced prostate cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).

The active participation of market players in expansions, partnerships, and mergers and acquisitions boosts the growth of the prostate cancer treatment market.

The scope of the prostate cancer treatment market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to global prostate cancer therapeutics market growth. Asia Pacific is expected to register the highest CAGR in the prostate cancer therapeutics market during 2022-2030. The growth of the prostate cancer therapeutics market in the US is mainly driven by the increasing incidence of prostate cancer cases, product launches, and government initiatives. Various product launches for the treatment of prostate cancer by companies are also bolstering the market growth. For instance, in June 2023, AstraZeneca and MSD's Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US for the treatment of adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). In addition, in November 2023, the FDA approved enzalutamide, a product manufactured by Astellas Pharma US, Inc. which is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) are a few key primary and secondary sources referred to while preparing the report on the prostate cancer treatment market.

1. INTRODUCTION

1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
- 1.3.1 Prostate Cancer Treatment Market - By Therapy Type
- 1.3.2 Prostate Cancer Treatment Market - By Distribution Channel
- 1.3.3 Prostate Cancer Treatment Market - By Region
  - 1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. PROSTATE CANCER TREATMENT MARKET LANDSCAPE

4.1. OVERVIEW
4.2. PEST ANALYSIS
- 4.2.1 North America - Pest Analysis
- 4.2.2 Europe - Pest Analysis
- 4.2.3 Asia-Pacific - Pest Analysis
- 4.2.4 Middle East and Africa - Pest Analysis
- 4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. PROSTATE CANCER TREATMENT MARKET - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. PROSTATE CANCER TREATMENT MARKET - GLOBAL MARKET ANALYSIS

6.1. PROSTATE CANCER TREATMENT - GLOBAL MARKET OVERVIEW
6.2. PROSTATE CANCER TREATMENT - GLOBAL MARKET AND FORECAST TO 2031
6.3. MARKET POSITIONING

7. PROSTATE CANCER TREATMENT MARKET - REVENUE AND FORECASTS TO 2031 - THERAPY TYPE

7.1. OVERVIEW
7.2. THERAPY TYPE MARKET FORECASTS AND ANALYSIS
7.3. HORMONAL THERAPY
- 7.3.1. Overview
- 7.3.2. Hormonal Therapy Market Forecast and Analysis
7.4. CHEMOTHERAPY
- 7.4.1. Overview
- 7.4.2. Chemotherapy Market Forecast and Analysis
7.5. IMMUNOTHERAPY
- 7.5.1. Overview
- 7.5.2. Immunotherapy Market Forecast and Analysis
7.6. TARGETED THERAPY
- 7.6.1. Overview
- 7.6.2. Targeted Therapy Market Forecast and Analysis
7.7. SURGERY
- 7.7.1. Overview
- 7.7.2. Surgery Market Forecast and Analysis
7.8. RADIATION THERAPY
- 7.8.1. Overview
- 7.8.2. Radiation Therapy Market Forecast and Analysis

8. PROSTATE CANCER TREATMENT MARKET - REVENUE AND FORECASTS TO 2031 - DISTRIBUTION CHANNEL

8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
- 8.3.1. Overview
- 8.3.2. Hospitals Market Forecast and Analysis
8.4. CLINICS
- 8.4.1. Overview
- 8.4.2. Clinics Market Forecast and Analysis
8.5. OTHERS
- 8.5.1. Overview
- 8.5.2. Others Market Forecast and Analysis

9. PROSTATE CANCER TREATMENT MARKET REVENUE AND FORECASTS TO 2031 - GEOGRAPHICAL ANALYSIS

9.1. NORTH AMERICA
- 9.1.1 North America Prostate Cancer Treatment Market Overview9.1.2 North America Prostate Cancer Treatment Market Forecasts and Analysis9.1.3 North America Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.1.4 North America Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.1.5 North America Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.1.5.1 United States Prostate Cancer Treatment Market
- 9.2.1 Europe Prostate Cancer Treatment Market Overview9.2.2 Europe Prostate Cancer Treatment Market Forecasts and Analysis9.2.3 Europe Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.2.4 Europe Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.2.5 Europe Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.2.5.1 Germany Prostate Cancer Treatment Market
- 9.3.1 Asia-Pacific Prostate Cancer Treatment Market Overview9.3.2 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis9.3.3 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.3.4 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.3.5 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.3.5.1 Australia Prostate Cancer Treatment Market
- 9.4.1 Middle East and Africa Prostate Cancer Treatment Market Overview9.4.2 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis9.4.3 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.4.4 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.4.5 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.4.5.1 South Africa Prostate Cancer Treatment Market
- 9.5.1 South and Central America Prostate Cancer Treatment Market Overview9.5.2 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis9.5.3 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.5.4 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.5.5 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.5.5.1 Brazil Prostate Cancer Treatment Market
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America

11. INDUSTRY LANDSCAPE

11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOINT VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. PROSTATE CANCER TREATMENT MARKET, KEY COMPANY PROFILES

12.1. JOHNSON AND JOHNSON
- 12.1.1. Key Facts
- 12.1.2. Business Description
- 12.1.3. Products and Services
- 12.1.4. Financial Overview
- 12.1.5. SWOT Analysis
- 12.1.6. Key Developments
12.2. ASTELLA PHARMA INC.
- 12.2.1. Key Facts
- 12.2.2. Business Description
- 12.2.3. Products and Services
- 12.2.4. Financial Overview
- 12.2.5. SWOT Analysis
- 12.2.6. Key Developments
12.3. SANOFI
- 12.3.1. Key Facts
- 12.3.2. Business Description
- 12.3.3. Products and Services
- 12.3.4. Financial Overview
- 12.3.5. SWOT Analysis
- 12.3.6. Key Developments
12.4. DENDREON PHARMACEUTICALS LLC
- 12.4.1. Key Facts
- 12.4.2. Business Description
- 12.4.3. Products and Services
- 12.4.4. Financial Overview
- 12.4.5. SWOT Analysis
- 12.4.6. Key Developments
12.5. CARDINAL HEALTH
- 12.5.1. Key Facts
- 12.5.2. Business Description
- 12.5.3. Products and Services
- 12.5.4. Financial Overview
- 12.5.5. SWOT Analysis
- 12.5.6. Key Developments
12.6. ASTRAZENECA
- 12.6.1. Key Facts
- 12.6.2. Business Description
- 12.6.3. Products and Services
- 12.6.4. Financial Overview
- 12.6.5. SWOT Analysis
- 12.6.6. Key Developments
12.7. BAYER AG
- 12.7.1. Key Facts
- 12.7.2. Business Description
- 12.7.3. Products and Services
- 12.7.4. Financial Overview
- 12.7.5. SWOT Analysis
- 12.7.6. Key Developments
12.8. TOLMAR INC
- 12.8.1. Key Facts
- 12.8.2. Business Description
- 12.8.3. Products and Services
- 12.8.4. Financial Overview
- 12.8.5. SWOT Analysis
- 12.8.6. Key Developments
12.9. ENDO PHARMACEUTICALS INC
- 12.9.1. Key Facts
- 12.9.2. Business Description
- 12.9.3. Products and Services
- 12.9.4. Financial Overview
- 12.9.5. SWOT Analysis
- 12.9.6. Key Developments
12.10. ABBVIE, INC.
- 12.10.1. Key Facts
- 12.10.2. Business Description
- 12.10.3. Products and Services
- 12.10.4. Financial Overview
- 12.10.5. SWOT Analysis
- 12.10.6. Key Developments